Display options
Cite
Kinyó Á, Hanyecz A, Lengyel Z, et al. Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid. J Clin Med. 2021;10(9)doi: 10.3390/jcm10091916.
Kinyó, �. �., Hanyecz, A., Lengyel, Z., Várszegi, D., Oláh, P., Gyömörei, C., Kálmán, E., Berki, T., & Gyulai, R. (2021). Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid. Journal of clinical medicine, 10(9), . https://doi.org/10.3390/jcm10091916
Kinyó, Ágnes, et al. "Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid." Journal of clinical medicine vol. 10,9 (2021). doi: https://doi.org/10.3390/jcm10091916
Kinyó Á, Hanyecz A, Lengyel Z, Várszegi D, Oláh P, Gyömörei C, Kálmán E, Berki T, Gyulai R. Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid. J Clin Med. 2021 Apr 28;10(9). doi: 10.3390/jcm10091916. PMID: 33925042; PMCID: PMC8125701.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2021 Apr 28;10(9). doi: 10.3390/jcm10091916.

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Journal of clinical medicine

Ágnes Kinyó, Anita Hanyecz, Zsuzsanna Lengyel, Dalma Várszegi, Péter Oláh, Csaba Gyömörei, Endre Kálmán, Tímea Berki, Rolland Gyulai

Affiliations

  1. Department of Dermatology, Venereology and Oncodermatology, University of Pécs Medical School Clinical Centre, H7632 Pécs, Hungary.
  2. Department of Pathology, University of Pécs Medical School Clinical Centre, H7632 Pécs, Hungary.
  3. Department of Immunology and Biotechnology, University of Pécs Medical School Clinical Centre, H7632 Pécs, Hungary.

PMID: 33925042 PMCID: PMC8125701 DOI: 10.3390/jcm10091916

Abstract

Bullous pemphigoid (BP) is an autoimmune blistering disease of elderly patients that has shown increasing incidence in the last decades. Higher prevalence of BP may be due to more frequent use of provoking agents, such as antidiabetic dipeptidyl peptidase-4 inhibitor (DPP4i) drugs. Our aim was to assess DPP4i-induced bullous pemphigoid among our BP patients and characterize the clinical, laboratory and histological features of this drug-induced disease form. In our patient cohort, out of 127 BP patients (79 females (62.2%), 48 males (37.7%)), 14 (9 females and 5 males) were treated with DPP4i at the time of BP diagnosis. The Bullous Pemphigoid Disease Area Index (BPDAI) urticaria/erythema score was significantly lower, and the BPDAI damage score was significantly higher in DPP4i-BP patients compared to the nonDPP4i group. Both the mean absolute eosinophil number and the mean periblister eosinophil number was significantly lower in DPP4i-BP patients than in nonDPP4i cases (317.7 ± 0.204 vs. 894.0 ± 1.171 cells/μL,

Keywords: DPP4; bullous pemphigoid; dipeptidyl peptidase-4 inhibitor; eosinophil; gliptin

References

  1. J Am Acad Dermatol. 2018 Oct 5;: - PubMed
  2. Am J Clin Dermatol. 2017 Aug;18(4):513-528 - PubMed
  3. J Dermatol Case Rep. 2014 Mar 31;8(1):24-8 - PubMed
  4. J Am Acad Dermatol. 2018 Dec;79(6):1034-1038.e5 - PubMed
  5. Dermatol Ther. 2020 Jul;33(4):e13790 - PubMed
  6. Front Med (Lausanne). 2018 Aug 20;5:220 - PubMed
  7. JAMA Dermatol. 2019 Feb 1;155(2):166-171 - PubMed
  8. JAMA Dermatol. 2018 Mar 1;154(3):347-350 - PubMed
  9. Croat Med J. 2020 Apr 30;61(2):93-99 - PubMed
  10. J Immunol. 2014 Nov 1;193(9):4415-28 - PubMed
  11. J Am Acad Dermatol. 2012 Mar;66(3):479-85 - PubMed
  12. JAMA Dermatol. 2018 Oct 1;154(10):1152-1158 - PubMed
  13. Int J Dermatol. 2018 Jul;57(7):810-816 - PubMed
  14. J Invest Dermatol. 2018 May;138(5):1201-1204 - PubMed
  15. J Eur Acad Dermatol Venereol. 2012 Feb;26(2):249-53 - PubMed
  16. BMJ Open Diabetes Res Care. 2021 Jan;9(1): - PubMed
  17. Am J Clin Dermatol. 2021 Jan;22(1):117-127 - PubMed
  18. Dermatology. 2017;233(5):401-403 - PubMed
  19. J Diabetes Investig. 2019 Mar;10(2):392-398 - PubMed
  20. Br J Dermatol. 2018 Sep;179(3):790-791 - PubMed
  21. Br J Dermatol. 2019 May;180(5):1267-1268 - PubMed
  22. Br J Dermatol. 2014 Nov;171(5):1223-6 - PubMed
  23. JAMA Dermatol. 2019 Feb 1;155(2):172-177 - PubMed
  24. J Clin Invest. 1998 Dec 15;102(12):2082-9 - PubMed
  25. J Dermatol. 2018 May;45(5):596-599 - PubMed
  26. Acta Derm Venereol. 2019 May 1;99(6):602-609 - PubMed
  27. J Diabetes Investig. 2018 Mar;9(2):445-447 - PubMed
  28. J Clin Pharm Ther. 2016 Jun;41(3):368-370 - PubMed
  29. Front Immunol. 2015 Jul 27;6:386 - PubMed
  30. JAMA Dermatol. 2016 Feb;152(2):224-6 - PubMed
  31. Br J Dermatol. 2016 Aug;175(2):296-301 - PubMed
  32. J Invest Dermatol. 2017 Jun;137(6):1199-1203 - PubMed
  33. Clin Exp Immunol. 2016 Jul;185(1):1-21 - PubMed
  34. J Invest Dermatol. 2009 Jul;129(7):1730-9 - PubMed
  35. J Am Acad Dermatol. 1987 Apr;16(4):879-81 - PubMed
  36. Actas Dermosifiliogr. 2020 Apr;111(3):249-253 - PubMed
  37. Diabetes Metab Syndr. 2020 May - Jun;14(3):213-216 - PubMed
  38. J Immunol. 2008 Jul 15;181(2):1120-7 - PubMed
  39. J Am Acad Dermatol. 2018 Mar;78(3):592-595 - PubMed
  40. Eur J Dermatol. 2018 Oct 1;28(5):711-713 - PubMed
  41. Front Biosci. 2008 Jan 01;13:1610-8 - PubMed
  42. Arch Dermatol. 1995 Jan;131(1):48-52 - PubMed
  43. Br J Dermatol. 2018 Nov;179(5):1141-1147 - PubMed
  44. J Invest Dermatol. 2012 Aug;132(8):1998-2004 - PubMed
  45. BMJ. 2008 Jul 09;337:a180 - PubMed
  46. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e438-e439 - PubMed
  47. Immunol Med. 2019 Mar;42(1):22-28 - PubMed
  48. J Invest Dermatol. 2019 Apr;139(4):835-841 - PubMed
  49. J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e153-e154 - PubMed
  50. J Immunol. 2010 Oct 15;185(8):4938-47 - PubMed
  51. Fundam Clin Pharmacol. 2015 Feb;29(1):112-4 - PubMed
  52. PLoS One. 2014 Sep 25;9(9):e107725 - PubMed
  53. J Am Acad Dermatol. 2018 Jun;78(6):1090-1096 - PubMed
  54. J Invest Dermatol. 2016 Dec;136(12):2495-2498 - PubMed
  55. Acta Derm Venereol. 2018 Nov 5;98(10):983-984 - PubMed
  56. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e439-e440 - PubMed
  57. Br J Dermatol. 2018 Jun;178(6):1462-1463 - PubMed
  58. J Invest Dermatol. 2016 Nov;136(11):2201-2210 - PubMed
  59. Clin Exp Immunol. 2004 Mar;135(3):497-504 - PubMed
  60. J Invest Dermatol. 2018 Jul;138(7):1659-1661 - PubMed
  61. Diabetes Care. 2018 Sep;41(9):e130-e132 - PubMed

Publication Types